Abstract Library

#3064 ALPPS for Neuroendocrine Liver Metastases Not Suitable for Conventional Hepatic Resection - Interim Analysis of the International ALPPS Registry

Introduction: Surgery is the most effective treatment option for neuroendocrine liver metastases (NELM). However, the majority of patients with NELM do not have disease that is resectable using conventional methods. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a relatively novel two-stage strategy in hepatic surgery.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Frilling A

Authors: Linecker M, Kambakamba P, Raptis D, Malago M, Ratti F,

Keywords: neuroendocrine, liver, metastases, surgery, ALPPS, two-stage, resection,

#3040 Palliative CT Brachytherapy in Hepatic Metastatic NET

Introduction: Hepatic metastases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) may induce prognosis relevant complications in an otherwise stable systemic disease after resection of the primary.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Jann H

Authors: Feldhaus F, Jann H, Jonczyk M, Boening G, Wieners G,

Keywords: brachytherapy, afterloading, hepatic metastases, local tumor ablation, local tumor control,

#2917 Quantification of Intratherapeutic SPECT/CT for Lutetium-177-DOTATOC PRRT in Neuroendocrine Tumors

Introduction: In PRRT for NET, feasibility of lesion uptake quantification in Lu-177-DOTATOC SPECT/CT for therapy monitoring remains unclear.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Galler M, Schatka I, Buch F, Bluemel S, Jann H,

Keywords: Lu-177-DOTATOC, PRRT, NET, dosimetry, SPECT/CT, Quantification,

#2914 Safety Profile and Adverse Events of Special Interest for Surufatinib in Chinese Patients with Advanced Extra-Pancreatic Neuroendocrine Tumors: Analysis of the Phase 3 SANET-ep Trial

Introduction: The previously reported SANET-ep trial (NCT02588170) demonstrated surufatinib significantly improves progression-free survival (PFS) in patients (pts) with advanced extrapancreatic neuroendocrine tumors (epNETs) compared to placebo; median PFS (9.2 vs. 3.8 months; HR = 0.334, 95% CI 0.223 to 0.499, p<0.0001).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Li J

Authors: Li J, Xu J, Zhou Z, Bai C, Chi Y,

Keywords: extra-pancreatic, neuroendocrine tumors, safety,

#2883 Comparison of Somatostatin Analogues in Metastatic Gastroenteropancreatic Neuroendocrine Tumors from a Bayesian Perspective: The GETNE-TRASGU Study

Introduction: Somatostatin analogues (SSA), octreotide LAR (Oct) and lanreotide autogel (Lan), significantly prolong progression-free survival (PFS) in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET). However, comparative data are not available and randomized trials comparing both SSAs are unlikely to be conducted.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Carmona-Bayonas A, Jimenez-Fonseca P, Lamarca A, Barriuso J, Castaño A,

Keywords: Bayesian model, octreotide, lanreotide, progression-free survival, efficacy,